达普罗杜斯塔特用于接受脏移植的接受者的移植后贫血
Yuichi Machida1, Tomoaki Iwai1, Kazuya Kabei1
1Department of Urology, Osaka Metropolitan University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
Transplantation proceedings
|February 14, 2024
概括
在移植后的贫血患者中,达普罗杜沙特有效地提高了血红蛋白水平,持续了12个月. 这种低氧诱导因子prolyl氧酶抑制剂显示出安全性和有效性,即使在那些对其他治疗无反应的人群中也是如此.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 达普罗杜斯塔特是一种低氧诱导因子酸酶抑制剂,对透析患者的贫血有效.
- 它在移植后贫血中的有效性仍然没有报告.
研究的目的:
- 评估达普罗德斯塔特作为治疗移植患者贫血的方法.
主要方法:
- 对21名移植后患者的分析,这些患者接受了至少12个月的达普罗杜斯塔特治疗.
- 在一年内评估血红蛋白,铁代谢,估计的淋巴膜过率 (eGFR) 和低密度脂蛋白 (LDL) 水平.
主要成果:
- 在12个月后,血红蛋白水平从10.1g/dL显著增加到12.6g/dL.
- 降低了费里丁和暂时降低了转林和度;EGFR和LDL水平保持稳定.
- 达普罗杜斯塔特被很好地容忍,并且可以调整剂量.
结论:
- 达普罗多斯塔特显著改善了移植后贫血中的血红蛋白水平.
- 这是一种安全,有效和剂量可调的选择,用于移植后的贫血,包括对ESA反应不足的患者.
更多相关视频
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
7.3K
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
7.6K
相关概念视频
Bone Marrow Sampling and Transplants
330
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
330
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Renal Failure: Dose Adjustments
89
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
89
